SeaStar Medical Holding Corporation
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Eric Schlorff
- Full Time Employees
- 18
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3513 Brighton Boulevard Denver CO United States of America 80216
- IPO Date
- Mar 18, 2021
- CIK
- 0001831868
- Website
- seastarmedical.com
- Similar Companies
- Business
- SeaStar Medical Holding Corporation (Nasdaq: ICU) is a commercial-stage medical technology company that develops and commercializes proprietary extracorporeal therapies to reduce the consequences of hyperinflammation on vital organs in critically ill patients. The company offers the Selective Cytopheretic Device (SCD), a disease-modifying platform therapy that neutralizes over-active neutrophils and monocytes to halt cytokine storms and destructive immune responses; QUELIMMUNE, an FDA-approved SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis/septic shock requiring continuous renal replacement therapy (CRRT); and NEUTRALIZE-AKI, an SCD therapy in pivotal clinical trials for adult patients with AKI requiring CRRT, with FDA Breakthrough Device Designation for multiple indications including cardiorenal syndrome, hepatorenal syndrome and myocardial stunning in end-stage renal disease. Founded in 2007 and headquartered in Denver, Colorado, SeaStar Medical operates primarily in the United States, targeting ICU patients with acute and chronic inflammatory conditions through integration with existing CRRT circuits and regional citrate anticoagulation. Recent developments include raising approximately $12.4 million in gross proceeds through equity offerings in June, July and August 2025 to extend its financial runway into 2026 and support SCD advancement; completing interim analysis of the NEUTRALIZE-AKI trial showing early favorable safety and efficacy trends; expanding trial sites to meet 2026 enrollment targets; reporting Q3 2025 net revenue of $183,000 with ongoing QUELIMMUNE sales growth; and implementing cost-saving measures to focus resources on the adult AKI market, which is 50 times larger than the pediatric segment.
Company News
ICU Medical to Participate in Upcoming Investor Conferences
SeaStar Medical Holding Corporation (ICU) Q2 2026 Earnings Call Transcript
SeaStar Medical Reports Second Quarter 2026 Financial Results and Provides Business Updates
ICU Medical Analysts Boost Their Forecasts Following Upbeat Q2 Earnings
ICU Medical Q2 Earnings Call Highlights
ICU Medical Announces Second Quarter 2026 Results and Updates its Fiscal Year 2026 Guidance
SeaStar Medical to Report Second Quarter Financial Results on August 12, 2026
ICU Medical Announces Time of Second Quarter 2026 Earnings Conference Call
SeaStar Medical Supports Advances in Critical Care of Pediatric Patients with Acute Kidney Injury (AKI)
SeaStar Medical Announces New ICD-10-PCS Codes for Its SCD Therapy for Acute Kidney Injury
SeaStar Medical to Present at Upcoming Investor Summit Conference
This ICU Medical Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
ICU Medical's General Counsel Sells — The Smiths Integration Is Almost Done, the Proof Isn'tICU Medical's General Counsel Sells — The Smiths Integration Is still playing out.
SeaStar Medical Holding Corporation (ICU) Q1 2026 Earnings Call Transcript
SeaStar Medical Reports First Quarter Financial Results and Provides Business Updates
Implied Volatility Surging for ICU Medical Stock Options
ICU Medical Announces First Quarter 2026 Results
SeaStar Medical to Report First Quarter Financial Results on May 13, 2026
ICU Medical Announces Time of First Quarter 2026 Earnings Conference Call
Ondine Biomedical shares rise 8% as ICU study shows nasal photodisinfection cuts pneumonia rates by nearly 40%